What’s Next After 20 Years Of NICE?
NICE's Growing Importance Has Brought Increasing Scrutiny
Meindert Boysen, head of NICE’s Centre For Health Technology Evaluation, shares advice for companies aiming to get their medicine to patients. His golden rules: engage in early advice and be more realistic about pricing.
You may also be interested in...
In case you missed it: catch up with snippets from interviews with industry leaders recently published by In Vivo.
UK HTA body NICE is looking to the future and rethinking its approach to data and how they inform its guidance.
Performance-based managed entry agreements need to be made more effective, but this can only happen if countries relax their stance on confidentiality and share information on MEAs amongst themselves, says a working paper from the OECD.